ABBOTT LABORATORIES Insider Trading Activity

Abbott Laboratories insider activity centers on a trust-related share transaction.

Rhea-AI Filing Summary

Abbott Laboratories insider activity centers on a trust-related share transaction. The Ford Family Trust, for which Chairman and CEO Robert B. Ford serves as co-trustee, reported a transaction involving 18,800 Abbott common shares on January 23, 2026 at a weighted average price of $107.1259 per share, executed in multiple trades between $106.735 and $107.485. After this activity, the trust held 216,203 Abbott shares indirectly attributed to Ford, while a separate line shows 253,305 Abbott shares held directly in his name.

Insider Trade Summary

Net Buyer: 18,800 shares

Net Buy 2 txns

Insider Ford Robert B

Role CHAIRMAN AND CEO

Bought 18,800 shs ($2.01M)

Type	Security	Shares	Price	Value
Purchase	Common shares without par value	18,800	$107.1259	$2.01M
holding	Common shares without par value	--	--	--

Holdings After Transaction: Common shares without par value — 216,203 shares (Indirect, Ford Family Trust); Common shares without par value — 253,305 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.735 to $107.485, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
2. F2. Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ABBOTT LABORATORIES (ABT) report for Robert B. Ford?

On January 23, 2026, a trust associated with Robert B. Ford reported a transaction in 18,800 Abbott common shares at a weighted average price of $107.1259 per share, executed across multiple trades.

Who actually holds the ABBOTT LABORATORIES (ABT) shares involved in this Form 4?

The Ford Family Trust DTD June 2, 2014 holds the shares related to the reported 18,800-share transaction, with Robert B. Ford serving as co-trustee of the trust.

How many ABBOTT LABORATORIES (ABT) shares does the Ford Family Trust hold after the reported transaction?

Following the reported activity, the Ford Family Trust held 216,203 Abbott common shares, reported as indirectly owned by Robert B. Ford.

How many ABBOTT LABORATORIES (ABT) shares are reported as directly owned by Robert B. Ford?

Separately from the trust, the filing shows 253,305 Abbott common shares as directly owned by Robert B. Ford.

What price range applied to the ABBOTT LABORATORIES (ABT) insider trades on January 23, 2026?

The filing notes that the trades were executed at prices ranging from $106.735 to $107.485 per Abbott share, resulting in a weighted average price of $107.1259.

What is Robert B. Ford’s role at ABBOTT LABORATORIES (ABT) as disclosed in this Form 4?

The filing identifies Robert B. Ford as both a Director and the Chairman and CEO of Abbott Laboratories.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/26/2026 - 08:02 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ford Robert B

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHAIRMAN AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	01/23/2026		P		18,800	A	$107.1259(1)	216,203(2)	I	Ford Family Trust
Common shares without par value								253,305	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.735 to $107.485, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.

	/s/ Robert B. Ford by Jessica H. Paik, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.